News

Prostate Cancer Study Identifies Numerous Subtypes of the Disease

  • Prostate cancer is the second most common cancer in men worldwide.
  • Integrative analysis led to the identification of 7 subtypes of prostate cancer.
  • Changes in signaling pathways and DNA repair genes may suggest new opportunities for therapy.

By Lisa Iype

Prostate cancer is the second most common cancer in men worldwide. The clinical behavior of prostate cancer is variable with some men exhibiting indolent prostate cancer which can be monitored over time while other men develop aggressive prostate cancer which can lead to metastasis and death.

Fig5_20150915

Figure from “The Molecular Taxonomy of Primary Prostate Cancer.”

As part of The Cancer Genome Atlas (TCGA) project, ISB researchers helped to analyze 333 primary prostate cancers by integrating data from DNA sequence, gene expression, microRNA expression, protein expression, and DNA methylation profiles. The study identified seven subtypes of prostate cancer reflecting the heterogeneity of this cancer. Approximately one-fourth of the samples could not be readily classified as a particular subtype. In the study, TCGA researchers also identified changes in signaling pathways and DNA repair genes which may suggest new opportunities for therapy.

The TCGA researchers compared their results to results from a recent multi-institutional study on metastatic prostate cancer (Integrative Clinical Genomics of Advanced Prostate Cancer) in order to identify molecular features which were similar and different between primary prostate cancer and treated metastatic prostate cancer. Many genes and pathways had increased alteration rates in the metastatic samples as compared to the primary prostate samples.

Title: “The Molecular Taxonomy of Primary Prostate Cancer”
Journal: Cell
Authors: The Cancer Genome Atlas Research Network
Link: Cell

TCGA Release: Read press release…

Recent Articles

  • 2021 Innovator Awards

    Three Collaborative Projects Announced for ISB’s 2021 Innovator Award Program

    ISB has kicked off the fifth year of its Innovator Award Program by announcing three collaborative and cross-disciplinary projects. The program was created in 2017 to support early-career scientists working on high-risk, high-reward innovations, and champions interdisciplinary collaboration for non-faculty ISB researchers.

  • CRI iAtlas

    CRI iAtlas Expands to Interactive Analysis of Data on Immunotherapy Treatments

    CRI iAtlas is a comprehensive web-based resource that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment. The iAtlas team released immuno-oncology modules that allow investigators to access and work with genomics data from trials of treatment with immune-checkpoint inhibitors.

  • Shmulevich-Thorsson

    ISB Researchers Among Recipients of AACR Team Science Award

    The American Association for Cancer Research (AACR) has recognized The Cancer Genome Atlas (TCGA) project with the 2020 AACR Team Science Awards. Award recipients include Dr. Ilya Shmulevich, ISB professor and head of the Shmulevich Lab; ISB senior research scientist Dr. Vésteinn Þórsson; and former Shmulevich Lab members Drs. Brady Bernard and Theo Knijnenburg.